RMD - Eli Lilly's GLP-1 impact on ResMed is overblown: Barron's
2024-07-13 15:34:06 ET
More on Eli Lilly, ResMed, etc.
- What Eli Lilly Is Getting With The Acquisition Of Morphic Holding
- Wall Street Lunch: Merger Monday In All Its Glory
- Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal
- Lilly expecting Q2 IPR&D pre-tax charge of around $0.14 per share: report
- These are the weight loss drug stocks with the most upside - SA Sentiment Survey